Furey Raymond J. 4
4 · RIGEL PHARMACEUTICALS INC · Filed Mar 1, 2024
Insider Transaction Report
Form 4
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Transactions
- Award
Employee Stock Option (right to buy)
2024-02-28+93,750→ 93,750 totalExercise: $0.90Exp: 2032-12-08→ Common Stock (93,750 underlying) - Award
Employee Stock Option (right to buy)
2024-02-28+78,500→ 78,500 totalExercise: $1.27Exp: 2034-01-23→ Common Stock (78,500 underlying)
Footnotes (3)
- [F1]The Reporting Person was granted an option with a performance-based condition with respect to 93,750 shares of the issuer's common stock on December 8, 2022. Thus, the exercise price of this option is $0.8965 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met.
- [F2]The Reporting Person was granted an option with a performance-based condition with respect to 78,500 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met.
- [F3]The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met.